Sodium Phosphates Injection, Solution
NDC Package 0409-7391-72

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

Sodium Phosphates (sodium phosphate, monobasic, monohydrate and sodium phosphate, dibasic, anhydrous) injection is sodium Phosphates Injection, USP, 3 mM P/mL is indicated as a source of phosphorus, for addition to large volume intravenous fluids, to prevent or correct hypophosphatemia in patients with restricted or no oral intake. This formulation utilizes a injection, solution delivery system. Marketed by Hospira, Inc., this product is identified by NDC 0409-7391 and is authorized under FDA application NDA018892.

Identification & Billing

NDC Package Code
0409-7391-72
Package Description
25 VIAL, SINGLE-DOSE in 1 TRAY / 15 mL in 1 VIAL, SINGLE-DOSE (0409-7391-82)
Product Code
0409-7391
11-Digit Billing Format
00409739172
Billing Unit
ML - Billing unit of "milliliter" is used when a product is measured by its liquid volume.
RxNorm Crosswalk
  • RxCUI: 1872384 - sodium phosphates (phosphorus 45 MMOL / sodium 60 MEQ) in 15 ML Injection
  • RxCUI: 1872384 - 15 ML sodium phosphate, dibasic 142 MG/ML / sodium phosphate, monobasic 276 MG/ML Injection
  • RxCUI: 1872384 - phosphorus 45 MMOL / sodium 60 MEQ per 15 ML Injection
  • RxCUI: 1872384 - sodium phosphate, dibasic 2.13 GM / sodium phosphate, monobasic 4.14 GM per 15 ML Injection
  • RxCUI: 1872384 - sodium phosphates (phosphorus 45 MMOL / sodium 60 MEQ) per 15 ML Injection

Clinical Specifications

Proprietary Name
Sodium Phosphates
Non-Proprietary Name
Sodium Phosphate, Monobasic, Monohydrate And Sodium Phosphate, Dibasic, Anhydrous
Substance Name
Sodium Phosphate, Dibasic, Anhydrous; Sodium Phosphate, Monobasic, Monohydrate
Dosage Form
Injection, Solution - A liquid preparation containing one or more drug substances dissolved in a suitable solvent or mixture of mutually miscible solvents that is suitable for injection.
Administration Route
Intravenous - Administration within or into a vein or veins.
Active Ingredient(s)
Usage Information
Sodium Phosphates Injection, USP, 3 mM P/mL is indicated as a source of phosphorus, for addition to large volume intravenous fluids, to prevent or correct hypophosphatemia in patients with restricted or no oral intake. It is also useful as an additive for preparing specific parenteral fluid formulas when the needs of the patient cannot be met by standard electrolyte or nutrient solutions. The concomitant amount of sodium (Na+ 4 mEq/mL) must be calculated into total electrolyte dose of such prepared solutions.

Regulatory & Marketing

Labeler Name
Hospira, Inc.
Product Type
Human Prescription Drug
FDA Application #
NDA018892
Marketing Category
NDA - A product marketed under an approved New Drug Application.
Start Marketing Date
06-02-2005
Listing Expiration
12-31-2027
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 0409-7391-72 identifies a specific commercial package of 25 vial, single-dose in 1 tray / 15 ml in 1 vial, single-dose (0409-7391-82) of Sodium Phosphates, a human prescription drug labeled by Hospira, Inc.. This injection, solution is formulated for intravenous use and contains sodium phosphate, dibasic, anhydrous; sodium phosphate, monobasic, monohydrate as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Hospira, Inc. on June 02, 2005. The current certification is valid through December 31, 2027.

How is this Hospira, Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 00409739172. Quantities are measured in per "ml or milliliter", products billed per milliliter are usually products measured by liquid volume.. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (4-4-2)
0409-7391-72
11-Digit CMS (5-4-2)
00409-7391-72

Note: The zero is added to the Labeler segment to maintain the 5-4-2 structure.